| case report | Q2782326 |
| scholarly article | Q13442814 |
| P50 | author | Brent A Hanks | Q57038308 |
| P2093 | author name string | April K Salama | |
| A Doran Bostwick | |||
| P2860 | cites work | Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease | Q61698785 |
| A case of tracheobronchitis in ulcerative colitis: a review of literature | Q64044138 | ||
| A rare extraintestinal manifestation of ulcerative colitis: tracheobronchitis associated with ulcerative colitis | Q82690918 | ||
| Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma | Q24629841 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses | Q33606166 | ||
| Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. | Q34657638 | ||
| CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma | Q35871798 | ||
| Immunomodulatory therapy for melanoma: ipilimumab and beyond | Q36841621 | ||
| Ipilimumab: controversies in its development, utility and autoimmune adverse events | Q37387037 | ||
| Ipilimumab in the treatment of metastatic melanoma: management of adverse events. | Q37601293 | ||
| Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy | Q37809156 | ||
| Management of immune-related adverse events and kinetics of response with ipilimumab | Q38012057 | ||
| Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease | Q38160763 | ||
| Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies | Q39828440 | ||
| Ipilimumab in patients with melanoma and autoimmune disease | Q41991133 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | patient | Q181600 |
| immunotherapy | Q1427096 | ||
| metastatic melanoma | Q18975855 | ||
| ipilimumab | Q2459042 | ||
| P304 | page(s) | 19 | |
| P577 | publication date | 2015-05-19 | |
| P1433 | published in | Journal for Immunotherapy of Cancer | Q27725163 |
| P1476 | title | Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis | |
| P478 | volume | 3 |
| Q46884498 | Adverse Events in Cancer Immunotherapy |
| Q90326662 | An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer |
| Q92021395 | Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer |
| Q96585230 | British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis |
| Q95841452 | Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders |
| Q36260666 | Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors |
| Q38845833 | Immune checkpoint inhibitors: a milestone in the treatment of melanoma |
| Q38931441 | Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? |
| Q39021248 | Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology |
| Q39044147 | Immuno-Oncology: The Third Paradigm in Early Drug Development |
| Q37131014 | Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management |
| Q54856582 | Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. |
| Q31034415 | Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper |
| Q38930084 | Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer |
| Q38972343 | Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. |
| Q87997894 | Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update |
| Q56892940 | RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer |
| Q39085984 | Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer |
| Q39044741 | Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature |
| Q60489259 | Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy |
| Q98771227 | Targeting the RANKL/RANK/OPG Axis for Cancer Therapy |
Search more.